vTv Therapeutics Inc. Files 8-K for Material Definitive Agreement

TL;DR

vTvT signed a big deal on 6/26, details TBD.

AI Summary

On June 26, 2024, vTv Therapeutics Inc. entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement, its counterparty, or any associated financial terms.

Why It Matters

This filing indicates a significant event for vTv Therapeutics Inc., likely involving a new partnership, acquisition, or significant transaction that could impact its business operations and future prospects.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the material definitive agreement.

Key Players & Entities

• vTv Therapeutics Inc. (company) — Registrant
• June 26, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.01 — stered Class A common stock, par value $0.01 per share VTVT NASDAQ Capital Market
• $20 m — ewsoara's payment of the upfront fee of $20 million, the Original License will be exp
• $41 million — requires Newsoara to pay vTv LLC up to $41 million in development milestones, $35 million
• $35 million — $41 million in development milestones, $35 million in sales-related milestones and royalti

Filing Documents

• vtvt-20240626.htm (8-K) — 23KB
• 0001641489-24-000054.txt ( ) — 143KB
• vtvt-20240626.xsd (EX-101.SCH) — 2KB
• vtvt-20240626_lab.xml (EX-101.LAB) — 21KB
• vtvt-20240626_pre.xml (EX-101.PRE) — 12KB
• vtvt-20240626_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On June 26, 2024, vTv Therapeutics LLC ("vTv LLC"), a subsidiary of vTv Therapeutics Inc., entered into the Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. ("Newsoara") (the "Second Amendment") to amend the License Agreement previously entered into between vTv LLC and Newsoara on May 31, 2018 (the "Original Agreement") . Under the Second Amendment, upon Newsoara's payment of the upfront fee of $20 million, the Original License will be expanded to a global license. Newsoara has up to one year from the date of the Second Amendment to pay the upfront fee; if it fails to do so, then the Second Amendment will be null and void. The Second Amendment also requires Newsoara to pay vTv LLC up to $41 million in development milestones, $35 million in sales-related milestones and royalties in the mid to upper single digits depending upon sales volumes. The foregoing description of the License Amendment is qualified in its entirety by reference to the Second Amendment, which the Company intends to file with the SEC as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. VTV THERAPEUTICS INC. By: /s/ Paul J. Sekhri Name: Paul J. Sekhri Title: Chairman, President, and Chief Executive Officer Dated: July 2, 2024

View Full Filing

View this 8-K filing on SEC EDGAR